In this report, we describe a novel gene therapy approach for hematopoietic stem/progenitor cells using a specific receptor-mediated gene transfection procedure to target c-kit+ cell lines. The vector consists of plasmid DNA containing a luciferase reporter gene that is condensed by electrostatic forces with polylysine (PL) covalently linked to streptavidin (binds biotinylated ligand) and PL covalently linked to adenovirus (AD; to achieve endosomal lysis) with the final addition of biotinylated steel factor (SLF-biotin).
A gene transfer system has been previously described that uses asialo-orosomucoid (ligand) to specifically target asialoglycoprotein receptors expressed on hepatocytes.' The vector was constructed by covalently linking asialo-orosomucoid to polylysine (PL) that, by electrostatic forces, binds and condenses DNA containing a reporter gene or other genes of interest (molecular conjugate vector).8 In subsequent studies, transferrin (TF) was included in the vector as the ligand instead of asialo-orosomucoid to target cells.9.'" Furthermore, the molecular conjugate vector was greatly improved by including endosomalytic agents such as adenovirus (AD) and fusenogenic peptides from influenza virus that mediate escape from endosomal lysis.""3 Endosomalytic reagents prevent endosomal degradation of entrapped DNA by destroying the endosomal membrane.
Human hematopoiesis is supported by the proliferation and differentiation of a small number of pluripotential stem ~e 1 l s . l~"~ These cells are responsible for maintaining sufficient numbers of committed hematopoietic cells for host survival. Therefore, these cells are the optimal target population for stable expression of transferred therapeutic genes (ie, adenine deaminase, glucocerebrosidase). In this regard, these stedprogenitor cell populations have been shown to express both c-kit (receptor for steel factor [SLF] ) and CD34 (ligand for L-selectin).'7-24 Thus, experiments presented here were designed to determine whether a molecular conjugate vector containing SLF could target gene transfer to c-kit' hematopoietic cells. The experiments in this report describe for the first time a versatile gene transfer vector that uses SLF to target hematopoietic cell lines that express c-kit.
MATERIALS AND METHODS
Chemical linkage of AD-PL. W 162 cells were cultured to SO% confluence in Dulbecco's modified Eagle's medium (GIBCO Life Technologies, Grand Island, NY) supplemented with penicillin/ streptomycin (GIBCO) and 10% fetal calf serum (Atlanta Biologicals, Norcross, GA) at 37"C, S% CO2, and then were infected with human type-S AD (d1014). Cells were harvested by centrifugation when a cytopathic effect was observed, and the supernatant was obtained from the infected W 162 cell pellet after 4 freeze-thaw Covalent linkage of streptavidin to PL (SA-PL). SA (Sigma) was linked to PL (Sigma) and separated as described previously.'' The SA and PL content were determined by optical density at 280 nm and 223 nm. A total of 1 mol of PL was modified with 0.16 mol of SA; the final concentration was 300 pg/mL PL and 40 pg/mL SA.
Cell lines and jZow cytometric analysis. HL-60, K562, MB02, M0-7e,26.27 and TF-I cells were maintained in RPM1 (GIBCO) supplemented with 10% fetal calf serum (Atlanta Biologicals), penicillidstreptomycin (GIBCO), and 2 mmol L-glutamine (GIBCO). Growth factor-dependent cell lines were maintained in cytokines as follows: MB02 cells in 30 ng/mL granulocyte-macrophage colonystimulating factor (GM-CSF; Peprotech, Rocky Hill, NJ); and MO7e and W-l cells in 30 ngUmL interleukin-3 (L-3; Peprotech). Expression of cell surface c-kit was determined by flow cytometric analysis. Briefly, 1 X IO5 cells in 100 pL of phosphate-buffered saline containing I% BSA were incubated with 10 ng of biotinylated SLF (SLF-biotin; R&D Systems, Minneapolis, MN) for 30 minutes at 4°C. washed, and then incubated with SA-fluorescein isothiocyanate (R&D Systems) for 30 minutes at 4°C. Cells were analyzed immediately on a Coulter Profile (Hialeah, FL) .
Construction of the molecular conjugate vector and transfection procedure. The targeted vector was constructed by adding 100 pL of AD-PL to 2 pg of reporter plasmid diluted in HBS for 30 minutes at room temperature. Then, 2 pL of SA-PL diluted in HBS was added and incubated for 30 minutes at room temperature. The control vector was constructed by adding an equimolar amount of PL instead of the SA-PL and incubated for 30 minutes at room temperature. As a final step, biotinylated Steel factor (SLF-biotin; R&D Systems) or biotinylated transferrin (TF-biotin; Sigma) was added and incubated for another 30 minutes at room temperature. A summary of the vector construction is shown in Fig 1. Log-phase growing cells (2 to 4 X lo6) were transfected by adding the complete vector or the control vector to cells in a 1.5-mL Eppendorf tube and incubated at 37°C for 2 hours. Cells were then returned to their normal growth conditions in a 25-mL flask. Cells (2 x IO6) were harvested 48 hours after transfection, washed 1 time with phosphate buffered saline, and then lysed in 200 pL of lysis buffer (Promega, Madison, WI). The lysate was pelleted by centrifugation, and the supernatant was collected for assay. Aliquots of each sample were collected to determine protein concentration (Pierce, Rockford, IL) and luciferase activity according to the procedures provided by Promega using a luminometer (Berthold, Bad Wildung, Germany), with a measuring time of 10 seconds. Each measurement was then adjusted to the sample's protein concentration by dividing relative light units (IUU) by protein (mg/mL).
RESULTS

SLF-targeted transfection of human hematopoietic cell lines.
To determine whether we could specifically target ckit+ hematopoietic cells, a molecular conjugate vector was constructed by condensing plasmid DNA containing the luciferase reporter gene with PL covalently linked to incompetent AD (AD-PL; provides escape from endosomal lysis) and PL covalently linked to SA (SA-PL; summarized in Fig  1) . In the final step, SLF-biotin was added to the vector. The control vector was similarly constructed except SA-PL was replaced with unconjugated PL; thus, SLF-biotin could not bind to the vector construct. Growth factor-dependent human MO-7e and MB02 hematopoietic cell lines (positive for ckit expression) and HL-60 and TF-1 cells (negative for ckit expression) were exposed to the SLF-targeted vector complexes or control vector complexes for 2 hours, returned to their normal growth conditions for 48 hours, and then harvested to determine luciferase reporter gene expression (Fig 2) . Whereas luciferase gene expression varied between cell lines that were transfected with the control vector, transfection with the SLF-targeted vector resulted in increased reporter gene expression in cell lines that expressed c-kit (MB02 and MO-7e) but not in cell lines that did not express c-kit (HL-60; see Fig 2) and TF-l (data not shown). It has been previously shown that the reporter gene expression obtained with the control vector is likely to be caused by the entry of the vector via AD receptors on the cell lines or through nonspecific ionic interactions with the PL. 28 Because SLF-targeted transfection should be dependent on the dose of SLF-biotin used in the molecular conjugate vector, MO-7e, MB02, and HL-60 cells were transfected with increasing amounts of SLF-biotin in the vector complex. Increasing the amount of SLF-biotin (maximum of 10 to 15 ng/mL) resulted in a dose-dependent increase in reporter gene expression (up to 12-fold) in MB02 ( Fig 3A) and MO-7e (Fig 3B) cells but not in HL-60 (Fig 3C) or TF-1 cells (data not shown).
SpecGcity of SLF-targeted transfection. To show specific entry of the targeted vector through the kit receptor, MB02 cells were preincubated with a 50-fold excess of SLF or IL-3 or with SR-1 monoclonal antibodies (MoAbs) that recognize c-kit and block the binding of SLF to its receptor before the addition of the SLF-targeted vector.
The expression of luciferase is presented in Fig 4 as the percentage of the RLU of the complete vector (100%; see Fig 4) . Whereas excess SLF effectively competed SLFtargeted transfection (luciferase gene expression was comparable with the control vector), IL-3, which does not bind to the c-kit receptor, had no effect. Furthermore, MB02 cells preincubated with SR-1 monoclonal antibodies also inhibited SLF-targeted transfection, whereas the isotype quired in the conjugate vector to escape endosomal lysis and control antibodies had no effect (Fig 4) . Thus, SLF-tar-for subsequent gene expression, the effect of removing AD geted transfection is specifically mediated through c-kit from the vector was examined. As shown above and shown receptors expressed on the hematopoietic progenitor cell here for comparison, the control vector gives 2.0 X lo4 5 lines.
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Role of endosomalytic agents in SLF-targeted transfecby including SLF-biotin (Fig 5) . However, substituting PL tion. To show that replication incompetent AD was refor AD-PL (endosomalytic agent) in the molecular conjugate Versatility of the molecular conjugate vector. Inclusion of SA linked to PL in the vector should generate a versatile vector that is dependent only on the biotinylated ligand used. Therefore, to show the versatility of the vector system, we compared SLF-targeted transfection with the previously described W transfection on hematopoietic progenitor cell lines using W-biotin to target the vector. As previously shown?" inclusion of W-biotin in the conjugate vector greatly increased (approximately 10-fold) the expression of luciferase in K562 cells above the amount produced by the control vector (Fig 6) . Furthermore, as would be predicted on the basis of c-kit expression, the SLF-targeted vector did not enhance luciferase gene expression in K562 cells, which do not express c-kit (Fig 6) .
Kinetics of conjugate vector exposure and vector expression of SLF-targeted transfection. To maximize gene expression in hematopoietic cells, we examined the kinetics of
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conjugate vector exposure to cells during the transfection period. MB02 cells were exposed to the molecular conjugate vector from 10 to 240 minutes, then returned to their normal growth conditions, and harvested 48 hours later to determine the expression of luciferase. MB02 cells showed increased gene expression when exposed to the conjugate vector up to 2 hours, after which gene expression decreased (Fig 7) . No loss in cell viability was observed after 2 hours of incubation with the conjugate vector (data not shown). Thus, a 2-hour incubation period results in maximum transfection efficiency. Next, we examined the kinetics of gene expression in SLF-targeted transfected MB02 and MO-7e (Figs 8B and C) cells and in "F-targeted K562 cells (Fig 8A) and found that maximum gene expression occurred after 30 hours and decreased thereafter. This decrease was slightly more rapid in MB02 and MO-7e cells, as compared with that in K562 cells. However, the maximum levels of gene expression in SLF-targeted transfection of MB02 and MO-7e cells (1.4 X lo6 light units) exceeded the maximum levels of gene expression in TF-infected K562 cells (5 X lo5 light units). Finally, to determine the frequency of gene transfer with this vector, MB02 cells were transfected with the SLF-targeted vector containing a P-galactosidase reporter gene, as described in the Materials and Methods. Cytocentrifuge preparations of transfected MB02 cells were stained for pgalactosidase activity, and then individual cells were scored for expression by transmission microscopy. Whereas untransfected MB02 cells showed no P-galactosidase activity, cells transfected with control vector and SLF-targeted vector were 9% and 97% positive, respectively (data not shown). Thus, the frequency of SLF-targeted transfection is very high and is comparable with the previously reported "F transfection in mouse hepatocytes."-13
DISCUSSION
As an alternative approach to widely used retroviruses for gene therapy, we explored the use of molecular conjugate vectors (PL-DNA complexes) to deliver genes to hematopoietic cells via the receptor-mediated endocytosis pathway. The molecular conjugate vector described here is made by combining plasmid DNA containing a gene of interest with PL to neutralize the charge on the DNA molecule that forms DNA toroids of less than 200 nm in size (summarized in Fig  1) . The PL contained in the vector is coupled to replication incompetent AD and provides a mechanism to escape lysosomal degradation of the DNA, and PL coupled to SA provides a mechanism to target the DNA toroids to specific cell types by the addition of biotinylated ligands. In this regard, hematopoietic stedprogenitor cells have been shown to express numerous growth factor receptors. However, c-kit has been shown to be expressed on murine pluripotential stem cells capable of reconstituting all hematopoietic lineages in irradiated recipient^:^." and c-kit is expressed on primitive human hematopoietic progenitor Furthermore, ckit expression is restricted to stedprogenitor cells and is not expressed on their committed progeny except for mast cells.22 Thus, the studies presented here used SLF-biotin to target the molecular conjugate vector to hematopoietic cell lines that express c-kit. In addition, the studies presented here used MO-7e cells because they, similar to their normal counterpart in the bone marrow, express CD34 and c-kit and are dependent on growth factors for their proliferation and survival. The data presented in this report show that the molecular conjugate vector can specifically target gene transfer to c-kit+ hematopoietic cell lines using SLF-biotin and that transfer to these cells is highly efficient.
Future studies will determine whether this vector can efficiently transfer genes into normal human hematopoietic progenitor cells that express c-kit. In addition, we will extend these studies to murine c-kit+ progenitor cells to develop an in vivo gene transfer strategy using this vector. Furthermore, because hematopoietic cells express numerous growth factor receptors, we would like to compare targeted transfection using other biotinylated cytokines such as GM-CSF and IL-3. Because the targeted transfection described above is highly efficient and expression is transient, this vector could A K562 
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be used to target human myeloid leukemias that variably express growth factor receptors with suicide genes for bone marrow purging ex vivo. Furthermore, therapeutic genes (cytokine genes) could be introduced into lymphoid cells using biotinylated IL-2 or other ligands for tumor vaccines and adoptive immunotherapy. Finally, SLF-targeted transfection provides the framework to develop a better vector to enhance stable integration into hematopoietic cells.
Because low levels of luciferase gene expression were observed with the control vector, we would like to determine in our system whether entry of the control vector into hematopoietic cells is nonspecific through ionic interactions via PL or specific through AD receptors expressed on hematopoietic cells. In this regard, we will include tRNA during the vector construction to neutralize any residual positively charged PL or antibodies to the AD knob proteins known to neutralize AD infection.
In summary, this gene therapy approach offers a number of unique features including that: (1) uptake of DNA relies on highly efficient receptor-mediated endocytosis, a physiologic pathway for macromolecular uptake not associated with cellular toxicity; (2) the vector is versatile in that targeting can be changed using different biotinylated ligands; (3) the vector can be prepared in large amounts and can package up to 48 kb of DNAz9; and (4) the DNA does not need to contain viral elements and obviates obvious potential safety hazards associated with retroviral vectors.29 In addition, although the efficiency of gene transfer via the receptormediated pathway is extremely high, the internalized DNA has been shown to be degraded after fusion of the endosome with lys~somes.'~ Because this effect is mediated by the viral capsid proteins and is independent of viral gene expression, AD genomic deletions, psoralen, and UV irradiation have been used to eliminate any potential safety hazards. 
